MX2017006200A - Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico. - Google Patents

Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.

Info

Publication number
MX2017006200A
MX2017006200A MX2017006200A MX2017006200A MX2017006200A MX 2017006200 A MX2017006200 A MX 2017006200A MX 2017006200 A MX2017006200 A MX 2017006200A MX 2017006200 A MX2017006200 A MX 2017006200A MX 2017006200 A MX2017006200 A MX 2017006200A
Authority
MX
Mexico
Prior art keywords
processes
intermediates
preparing
dicarboxylic acid
terminated dialkane
Prior art date
Application number
MX2017006200A
Other languages
English (en)
Inventor
Carmen Daniela Oniciu
Joseph Geoffroy Otto
Original Assignee
Gemphire Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics Inc filed Critical Gemphire Therapeutics Inc
Publication of MX2017006200A publication Critical patent/MX2017006200A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/62—Use of additives, e.g. for stabilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/04—Seven-membered rings not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente exposición proporciona un proceso para la preparación de los compuestos de la fórmula (III), (ver Fórmula) los compuestos de la fórmula (V), (ver Fórmula) y las sales correspondientes de la fórmula (IV). (ver Fórmula) Los compuestos producidos mediante los métodos y procesos de la invención son particularmente útiles para su administración en humanos y animales.
MX2017006200A 2014-11-14 2015-11-16 Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico. MX2017006200A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462079894P 2014-11-14 2014-11-14
PCT/US2015/060917 WO2016077832A2 (en) 2014-11-14 2015-11-16 PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS

Publications (1)

Publication Number Publication Date
MX2017006200A true MX2017006200A (es) 2017-11-17

Family

ID=54705886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006200A MX2017006200A (es) 2014-11-14 2015-11-16 Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.

Country Status (14)

Country Link
US (4) US10227285B2 (es)
EP (2) EP3218349A2 (es)
JP (2) JP2017533973A (es)
KR (1) KR20170083535A (es)
CN (2) CN107108442A (es)
AU (1) AU2015346037A1 (es)
BR (1) BR112017009876A2 (es)
CA (1) CA2966631A1 (es)
HK (1) HK1244265A1 (es)
IL (1) IL252245A0 (es)
MX (1) MX2017006200A (es)
RU (1) RU2017118432A (es)
SG (2) SG10201912713YA (es)
WO (1) WO2016077832A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017006200A (es) * 2014-11-14 2017-11-17 Gemphire Therapeutics Inc Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.
WO2018165120A1 (en) * 2017-03-06 2018-09-13 Gemphire Therapeutics Inc. Effect of carboxyalkylethers on obesity symptoms and lipodystropy
CA3059073A1 (en) * 2017-04-18 2018-10-25 Daniela Carmen Oniciu Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
KR20210093900A (ko) * 2018-10-18 2021-07-28 젬파이어 세러퓨틱스 인코포레이티드 젬카빈, 이의 약학적으로 허용가능한 염, 이의 조성물 및 이의 사용 방법
WO2021021563A1 (en) 2019-07-26 2021-02-04 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
US11730712B2 (en) 2021-01-25 2023-08-22 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
WO2022159808A2 (en) 2021-01-25 2022-07-28 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2033909A (en) 1934-12-19 1936-03-17 Niacet Chemicals Corp Manufacture of calcium levulinate
US3971816A (en) 1973-11-26 1976-07-27 Ceskoslovenska Akademie Ved Esters of carboxylic acids formally substituted by sodium or potassium in the alpha-position and the method for their preparation
DE2446753C2 (de) * 1974-10-01 1982-04-22 Deutsche Texaco Ag, 2000 Hamburg Verfahren zur Herstellung von äthylenisch ungesättigten Dicarbonsäuredialkylestern
CA1197242A (en) 1983-03-02 1985-11-26 Jean A. Gauthier Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
US4691034A (en) 1986-04-14 1987-09-01 Texaco, Inc. Purification of propylene oxide by treatment with calcium hydroxide in glycerol or sugar water
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
BR9815548A (pt) 1997-07-31 2000-11-07 Kos Pharma Inc Composição farmacêutica para administração em dose única diária para alteração de lipìdios num indivìduo sem causar hepatotoxicidade induzida por drogas, miopatia ou rabdomiólise, comprimido revestido para administração oral e método para administração de dita composição
US6861555B2 (en) * 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US6239300B1 (en) 1999-02-17 2001-05-29 Phillips Petroleum Company Metallocene production process
EP1204626B1 (en) 1999-04-01 2008-01-16 Esperion Therapeutics Inc. Ether compounds, compositions, and uses thereof
KR20020073182A (ko) * 2000-01-25 2002-09-19 워너-램버트 캄파니 칼슘 디카르복실레이트 에테르, 이의 제조 방법 및 이에의한 혈관 질환 및 당뇨병의 치료 방법
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
PL361310A1 (en) 2000-10-13 2004-10-04 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
US20040192771A1 (en) 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
DE10211289A1 (de) 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
CA2505915A1 (en) * 2002-11-15 2004-06-03 Warner-Lambert Company Llc Method of lowering crp and reducing systemic inflammation
WO2004078109A2 (en) 2003-03-07 2004-09-16 Merck Sharp & Dohme Limited PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ανβ3 RECEPTOR ANTAGONISTS
WO2005002557A1 (en) 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US7345190B2 (en) * 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
US20090208539A1 (en) 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
EP1858480B3 (de) * 2005-03-17 2020-05-06 Cognis IP Management GmbH Kosmetische zusammensetzungen enthaltend ester auf basis von 2- propylheptanol
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US7714127B2 (en) 2005-10-06 2010-05-11 Boehringer Ingelheim Pharmaceuticals, Inc. Process for making heteroaryl amine intermediate compounds
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
JP5280007B2 (ja) * 2006-08-02 2013-09-04 株式会社クレハ ヒドロキシカルボン酸の精製方法、環状エステルの製造方法およびポリヒドロキシカルボン酸の製造方法
US7777071B2 (en) 2006-08-11 2010-08-17 Ssv Therapeutics, Inc. Production of carnitine conjugate intermediates
CA2661613C (en) 2006-08-25 2016-01-26 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
FI20080353A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi
WO2008081891A1 (ja) 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤
WO2008124505A2 (en) 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
WO2008141130A1 (en) * 2007-05-11 2008-11-20 Kosan Biosciences, Inc. Process for the preparation of epothilones
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009048938A1 (en) * 2007-10-08 2009-04-16 Keen Ingredients, Inc. Quinoa grain processing and products
SI2230932T1 (sl) 2008-01-10 2017-07-31 Evonik Roehm Gmbh Oplaščeni farmacevtski ali nutracevtski pripravek s povečanim sproščanjem aktivne učinkovine v črevesu
US20090226515A1 (en) 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
FR2928925B1 (fr) * 2008-03-19 2011-01-07 Centre Nat Rech Scient Complexes de bore ou d'aluminium, et leurs utilisations.
EP2285352A2 (en) 2008-05-13 2011-02-23 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
MX2010012514A (es) 2008-05-20 2011-05-30 Cerenis Therapeutics S A Niacina y un medicamento nsaid para tratamiento combinado.
US8937063B2 (en) 2010-06-24 2015-01-20 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
AU2011350396A1 (en) 2010-12-27 2013-07-11 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
EP2658536B1 (en) 2010-12-27 2016-10-19 Gemphire Therapeutics Inc. Gemcabene and derivatives for treating pancreatitis
UA112539C2 (uk) * 2011-03-03 2016-09-26 Новартіс Аг Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
JP2014516080A (ja) 2011-06-08 2014-07-07 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
WO2013084237A1 (en) 2011-12-08 2013-06-13 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
EP2800564B1 (en) 2012-01-06 2020-05-06 NeuroBo Pharmaceuticals, Inc. Compound for use in methods of reducing risk of cardiovascular disease
MX2017006200A (es) 2014-11-14 2017-11-17 Gemphire Therapeutics Inc Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.
EP3370713A4 (en) 2015-11-06 2019-10-23 Gemphire Therapeutics Inc. TREATMENT OF MIXED DYSLIPIDEMIA
CA3059073A1 (en) 2017-04-18 2018-10-25 Daniela Carmen Oniciu Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor

Also Published As

Publication number Publication date
WO2016077832A3 (en) 2016-07-07
KR20170083535A (ko) 2017-07-18
JP6731990B2 (ja) 2020-07-29
CA2966631A1 (en) 2016-05-19
US20220402854A1 (en) 2022-12-22
US20170158601A9 (en) 2017-06-08
EP3653598A1 (en) 2020-05-20
US20200048181A1 (en) 2020-02-13
US20180194713A1 (en) 2018-07-12
JP2019048838A (ja) 2019-03-28
US20160137584A1 (en) 2016-05-19
RU2017118432A (ru) 2018-12-14
CN107108442A (zh) 2017-08-29
CN111704543A (zh) 2020-09-25
RU2017118432A3 (es) 2019-06-06
HK1244265A1 (zh) 2018-09-14
WO2016077832A2 (en) 2016-05-19
JP2017533973A (ja) 2017-11-16
EP3218349A2 (en) 2017-09-20
SG11201702496XA (en) 2017-04-27
BR112017009876A2 (pt) 2017-12-19
SG10201912713YA (en) 2020-02-27
AU2015346037A1 (en) 2017-07-06
IL252245A0 (en) 2017-07-31
US10227285B2 (en) 2019-03-12

Similar Documents

Publication Publication Date Title
MX2017006200A (es) Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
IN2014CH00247A (es)
PH12017500833A1 (en) Synthesis of copanlisib and its dihydrochloride salt
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
MX2017002214A (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno.
PH12016502229A1 (en) Process for preparing phosphorus-containing cyanohydrins
IN2014MU00455A (es)
MX2016015464A (es) Composicion farmaceutica oral de isotretinoina.
MX2016015543A (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno.
PH12014501712B1 (en) Novel morpholinyl derivatives useful as mogat-2-inhibitors
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
MX2017011389A (es) Proceso para la preparacion de 3-cloro-2-vinilfenilsulfonatos.
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
MA40312A (fr) Composition pharmaceutique orale d'isotrétinoïne
PL3166978T3 (pl) Sposób wytwarzania stabilnych względem zamrażania i rozmrażania dyspersji wodnych
MA40447A (fr) Composition pharmaceutique orale d'isotrétinoïne
MX361770B (es) Método para la preparación de 1-alquil-3-difluorometil-5-fluor-1h- pirazol-4-carbaldehídos y 1-alquil-3-difluorometil-5-fluor-1h-pira zol-4-carboxilatos.
IN2014CH00304A (es)
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
TW201612142A (en) Process for preparing 3-chloro-2-vinylphenol
IN2014MU00072A (es)

Legal Events

Date Code Title Description
FG Grant or registration